Shayan et al. showed that combination therapies with the addition of a PD-1 inhibitor to the anti-EGFR antibody cetuximab and toll-like receptor agonist (TLR8) motolimod could augment the antitumor response in HNSCC [85]. Here, PDCD1 is linked to head and neck squamous cell carcinoma.